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ABSTRACT: During T-cell maturation, thymocytes interact with thymic stromal major histocom* 
patibility complex (MHC) determinants and thymic hormones, and proliferate, apparently in 
response to MHC gene products, in the absence of antigen. The maturing thymocytes also express 
a series ofcellsurface molecules, at one stage coexpressing T4, T6, and TS. Mature T cells express 
either T4 or T8, lack T6, bear the T3-Ti receptor complex on the cell surface, and require antigen 
in addition to MHC determinants to proliferate. To study whether DNA methylation may be 
involved in regulating phenotypic and functional changes observed during thymocyte maturation, 
cloned, T4 + Interleukin-2 dependent, antigen-specific T cells were treated with an inhibitor of 
D N A  methylation, 5-azacytidine (5-azaC). The 5-azaC treated cells lost the requirement for 
antigen and could be activated by autologous macrophages alone. Anti-class II and anti-T3, but 
not anti-class I monoclonal antibodies, inhibited activation of 5-azaC treated T4 + cells by 
macrophages, implying that the T3-Ti  receptor complex may be recognizing class II MHC molecules 
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I N T R O D U C T I O N  
H u m a n  T lymphocytes derive f rom precursors in the bone marrow, which migrate 
as prothymocytes  to the thymus. In the thymus, these cells interact with products 
of  the major  histocompatibility complex (MHC) plus thymic hormones,  and in 
response to these signals, differentiate into T cells [1-5] .  During maturation, the 
thymocytes  express a series of  cell surface molecules identified by monoclonal  
antibodies. Stage I thymocytes are T l l  + T 6 -  T 4 -  T 8 -  T 3 - ,  while stage II 
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thymocytes are T l l  + T6 + T4 + T8 ÷ T3 and stage III thymocytes are T l l  ÷ 
T6 T4 + T 8 -  T3 + or T l l  + T 6 -  T4 T8 ÷ T3 ÷ [6,7]. The T-cell receptor,  
associated with T3, appears only on the surface of  stage III thymocytes [7]. 
During this process, a majority of  the thymocytes proliferate, apparently in re- 
sponse to self class II MHC gene products without antigen, and more than 60% 
of  thymocytes die in the thymus [1,3,8]. In contrast to thymocytes, the mature 
T cell entering the peripheral circulation must recognize antigen in addition to 
self MHC  products to proliferate. 
Selective activation and suppression of  gene expression presumably mediates 
the phenotypic and functional changes observed in maturing thymocytes. One 
mechanism governing gene transcription is D N A  methylation. In many systems, 
unmethylated D N A  sequences can be shown to correlate with gene expression, 
while methylated sequences are transcriptionally inactive [9-16] .  In particular, 
hypomethylation of  regulatory sequences 5' to the structural sequences appear 
to correlate with active transcription of  the structural sequences [9,12,14]. 
5-azacytidine (5-azaC) is a nucleoside analog that alters D N A  methylation. 5- 
azaC, when added to proliferating cells, prevents methylation of  newly synthe- 
sized D N A  by inhibiting D N A  (cytosine-5-)-methyltransferase, an enzyme that 
methylates cytidine in CpG sequences on the daughter D N A  strand when mCpG 
is identified in the parent D N A  strand [ 17,18]. Cells treated with 5-azaC express 
new functional and histologic features when D N A  methylation is inhibited 
[15,19-23] .  Thus, 5-azaC is a convenient tool to induce expression of  genes 
suppressed by D N A  methylation. 
To test whether  D N A  methylation may be involved in the phenotypic func- 
tional changes observed during thymic maturation, we treated cloned, antigen- 
specific Interleukin-2 (IL-2) dependent  T4 + and T8 + human T-cell lines with 5- 
azaC. In this report,  we demonstrate that antigen-specific T4 ÷ cells, when treated 
with 5-azaC, proliferate to autologous class II MHC determinants analogous to 
the less mature thymocyte. No  changes in the phenotype of  the mature T4 + 
cells were observed. 
M A T E R I A L S  A N D  M E T H O D S  
Isolation of peripheral blood mononuclear cells (PBMCs). Heparinized peripheral 
venous blood obtained from normal volunteers was centrifuged at 300 x g for 
10 min at room temperature; the buffy coat aspirated, and PBMCs separated by 
density gradient centrifugation on Ficoll-Paque (Pharmacia, Piscataway, NJ) ac- 
cording to the method of  Boyum [24]. PBMCs were stored frozen in liquid 
nitrogen, and thawed according to the method of  Donaldson et al. [25]. Viability 
of  the thawed cells is usually > 9 7 %  by trypan blue exclusion. 
Purification of adherent cells. Adherent  cells were isolated by allowing PBMCs to 
bind to 60 x 15 mm plastic petrie dishes (Falcon #1007,  Oxnard, CA) for 45 
min in RPMI 1640 (GIBCO, Grand Island, NY) containing 10% human AB 
serum. Nonadheren t  cells were rinsed off  with RPMI 1640, and adherent cells 
were removed by adding 5 ml of  RPMI 1640/10% AB serum/24 mM lidocaine 
for 15 min at room temperature,  followed by three washes with RPMI at 4°C. 
This population is referred to as macrophages (MO). 
IL-2-dependent T-celllines. A volunteer was boosted with tetanus toxoid. Fourteen 
or more days later, PBMCs were isolated and cultured in round bottomed 96- 
well microtiter plates (Nunc, from GIBCO  Laboratories, Grand Island, NY) in 
458 B. Richardson 
RPMI 1640 containing 10% AB serum, 100 U/ml penicillin, 100 ~g/ml strep- 
tomycin, and nonalum absorbed tetanus toxoid (TT) (Wyeth, Marietta, PA) at a 
final dilution of 1:50. Cultures were maintained at 37°C in a humidified incubator 
in an atmosphere of 5% CO2. After 4 days the cells were transferred into com- 
plete medium containing RPMI 1640, 20% AB serum, penicillin, streptomycin, 
and 20% IL-2 (supernatant from the MLA-144 cell line) [26]. After several 
doublings of total cell numbers, the T cells were cloned by limiting dilution at 
0.2 cells/well into flat bottomed microtiter wells (Nunc) containing 105 mito- 
mycin-C treated or irradiated (2000 R) autologous PBMCs, complete medium, 
and TT. Cloned lines were maintained in 24 well plates (Nunc) by weekly re- 
challenge with 106 irradiated (2000 R) or mitomycin-C inactivated PBMC/well 
plus TT, and twice weekly addition of fresh complete medium. 
Phenotype of cloned T-cell lines. T-cell phenotype was determined using the OKT4 
(Ortho Pharmaceuticals, Raritan, NJ) and Leu-2 (Becton-Dickinson, Mountain 
View, CA) monoclonal antibodies. Cells stained with fluorescein isothiocyanate 
(FITC) and phycoerythrin (PE) conjugated antibodies were analyzed with a Coul- 
ter EPICS V or C flow cytometer, using a modification of the procedures pre- 
viously described [27,28]. 
Proliferation assay. T-cell proliferation assays were performed by washing IL-2 
dependent T cells free of IL-2, then culturing 2 x 10 ~ to 104 T cells with graded 
numbers of mitomycin-C treated or irradiated (2000 R) MO in media containing 
RPMI 1640, 10% AB serum, 100 U/ml penicillin, and 100 tzg/ml streptomycin. 
The cells were cultured in round-bottomed 96 well microtiter plates in a total 
volume of 200 microliters per well. Antigen was added at varying concentrations. 
In some experiments, 20 ~l of IL-2 containing supernatant was added to each 
well on day 3, and 5 ~Ci tritiated thymidine (~H-TdR) (New England Nuclear, 
Boston, MA) was added to each well on day 5. Sixteen hours later, the cells were 
harvested onto glass fiber filters with a Mini-MASH (Microbiological Associates, 
Walkersville, MD), dried, and radioactivity measured with a Packard 574 liquid 
scintillation spectrophotometer. Results are expressed as the mean of triplicate 
wells ± SEM. In experiments using monoclonal antibodies to inhibit activation, 
the antibodies were used at a final concentration of 100 ng/ml with the exception 
of 1.41, which was used at 1 ng/ml. 
Reagents and monoclonal antibody binding assay. 5-azacytidine, cycloheximide, so- 
dium butyrate, actinomycin D, and hydroxyurea (HU) were purchased from 
Sigma Chemical Corporation (St. Louis, MO). Candida albicans (C.alb.) was pur- 
chased from Hollister-Stier, Spokane, WA. Anti-T3, anti-T6, and anti-T4a an- 
tibodies were purchased from Ortho Pharmaceuticals (Raritan, NJ) and anti-HLA 
A,B,C from Cappel Laboratories (Cochranville, PA). The 1.41 B cell hybrid 
secreting anti-HLA D framework antibody was a generous gift from Dr. H. 
McDevitt [29]. Monoclonal antibody concentration was determined by an ELISA 
technique [30,31] using class-specific antisera (Litton Bionetics, Kensington, MD) 
to coat 96 well plates (Nunc Immuno-Plate I, from GIBCO). Test samples or 
serial dilutions of known amounts of purified myeloma protein of the appropriate 
immunoglobulin class (Litton Bionetics) were allowed to bind to the coated wells. 
Horseradish peroxidase conjugated goat anti-mouse IgG (Sigma) was used to 
detect bound mouse immunoglobulin. The assay was developed with O-dianis- 
idine and color development was measured in a Titertek Multiskan (Flow Lab- 
oratories Inc., McLean, VA). Full details are provided elsewhere [31]. 
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RESULTS 
5-azaC Trea ted ,  T4 + Ant igen Reactive T Cells Can Respond to MO 
Without Antigen 
Cloned Interleukin-2 (IL-2) dependent human T-cell lines were obtained by 
immunizing a volunteer with TT, in vitro stimulation of peripheral blood mono- 
nuclear cells with TT, and cloning by limiting dilution. Four cloned lines, TT16E, 
TT 18I, TT 18M, and TT 18X, were obtained which were T4 + T8 - as determined 
by flow cytometry. The reactivity of the lines with TT was tested by culturing 
the lines with mitomycin-C treated PBMCs and serial dilutions of TT. All four 
lines responded to TT in a dose-dependent fashion (Table 1), demonstrating that 
each line was TT reactive. TT16E did not react with C.alb., an unrelated antigen. 
Thymocytes, in contrast to mature T cells, proliferate in response to autologous 
class II molecules in the absence of antigen [1,3]. To test whether 5-azaC could 
induce these cloned, T4 + antigen reactive cells to respond to class II MHC 
molecules alone, 5-azacytidine (0.25-4/*M) was added to subcultures of TT18X. 
Four to 6 days after treatment the cells were washed and tested for reactivity to 
varying number of autologous MOs with and without antigen. The results are 
shown in Figure 1. The cloned T4 + antigen reactive T-cell line, when treated 
with 5-azaC, acquired the ability to respond to autologous MOs without antigen, 
while untreated cells required both antigen and macrophages. The optimal 5- 
azaC concentration for TT18X was 1.0 tzM; lower concentrations were ineffec- 
tive, while higher concentrations proved toxic. For convenience, the 5-azaC 
induced proliferative response to MO without antigen will be referred to as 
"5-azaC induced self-reactivity." 
The response of both untreated and 5-azaC treated TT18X to TT presented 
by MO is less than the response observed when unfractionated PBMCs are used 
as antigen presenting cells (APC). This was observed for all cloned T-cell lines 
tested (see also Table 2), and may represent suppression by the MO [32] or 
depletion of more potent antigen presenting cells [33]. However, the use of 
purified MOs permits a more precise enumeration of HLA-D bearing APCs and 
minimizes the possibility that other cell populations, such as regulatory T cells, 
are responsible for or involved in the abnormal responses seen in 5-azaC treated 
cells. Furthermore, the use of purified MOs allows us to tentatively identify the 
stimulating cell as the MO, although a response to a minor contaminating sub- 
population cannot be excluded. For these reasons, all studies were performed 
TABLE 1 Reactivity of cloned T-cell lines (Proliferation of cloned lines (CPM _+ SEM)) 
A n t i g e n  D i l u t i o n  T T 1 6 E  ~ T T 1 8 I  a T T 1 8 M  ~ T F 1 8 X  a 
T T  1:4 3 , 7 6 8  + 571 2 , 8 5 4  + 12 12 ,392  -+ 6 8 8  10 ,431  + 3 ,051  
T T  1:8 1 0 , 1 5 7  -+ 2 , 2 9 1  4 , 2 5 1  + 1 ,655  11 ,644  -+ 2 , 4 2 8  12 ,665  + 1 ,251 
T T  1:16 1 1 , 0 3 3  -+ 7 0 0  9 , 1 6 3  -+ 2 , 5 7 6  8 , 5 5 3  -+ 1 , 5 5 0  1 0 , 7 6 2  + 4 8 0  
1:32 nd  b 1 4 , 0 8 7  + 3 , 0 9 7  2 , 8 4 6  ± 2 , 4 5 9  4 , 4 5 6  + 2 , 1 1 5  
c .a lb  1:6 3 8 4  -+ 23 nd  b nd  b nd ~ 
1:18 1 , 3 6 6  -+ 5 2 0  
1:54 8 9 3  -4- 179  
N o n e  8 3 2  -+ 179  3 , 5 7 0  -+ 101 2 1 8  + 193 171 + 36  
~10 '* cloned T cells were cultured with 10 ~ mitomycin-C treated PBMCs in 0.2 ml of  RPMI 1640/10% AB serum plus antigen. 
Twenty milliliters of  IL-2 containing supernatant was added on day 3 and proliferation measured on day 6 by 5H-TdR 
incorporation. Results are expressed as the mean _+ SEM of  triplicate cultures. 
hnd: not done. 
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FIGURE 1 Cloned T cells were treated with 1.0/zM 5oazaC and 6 days later 104 treated 
and untreated cells were cultured with graded numbers of mitomycin-C treated MOs 
(156-10,000/well) with (A) or without (B) TT diluted 1:50. Twenty microliters of Inter- 
leukin-2 were added on day 3, and proliferation was measured on day 6 by incorporation 
of 3H-TdR. The ordinate scale is the same in both panels. 
with MOs rather than PBMCs, although the MOs frequently gave lower prolif- 
erative responses. 
To test whether  5-azaC induced self-reactivity was unique to the TT1 8 X  cloned 
line, the three other  T4 ÷ TT  reactive cloned lines were similarly treated with 5- 
azaC, then challenged with autologous MO with and without antigen. These 
experiments are summarized in Table 2. 5-azaC not only induces self-reactivity 
in TT18X,  but in TT18I,  TT16E, and TT18M as well. Of  note is that both TT18I  
and TT18M required 1.0/zM 5-azaC while 0 .5/zm was most effective in TT16E 
(data not shown). This variability in optimal 5-azaC concentration, although slight, 
was reproducible. In these studies the optimal T cell: MO ratio for activating 5- 
azaC treated T cells was found to be 1:1, and this ratio was used in subsequent 
studies. When the results presented in Figure 1 and Table 2 are compared, it 
can be seen that in some experiments the proliferative response of  5-azaC treated 
cells to MO plus TT  was greater than the response to MO alone, while in other 
experiments the opposite is true, and occasionally the responses are of equal 
magnitude (Figure 1). The relative magnitudes of  the responses varied between 
experiments,  even for the same line, and the reason is not clear. However ,  an 
explanation could be that only a fraction of  5oazaC treated cells change phenotype 
[15], resulting in fewer cells responding to MO without TT. Moreover,  the 
resulting two populations may express different growth rates, resulting in changes 
in the relative proportions of  the phenotypes. The MO responsive phenotype 
was routinely stable for at least 2 weeks. After this time, variable results were 
obtained, and for this reason, subsequent studies were performed 4 -1 4  days after 
5-azaC treatment. To  test whether the variability observed over time was due to 
instability of  the 5-azaC induced changes or to more rapid growth of cells activated 
by both MO and antigen, attempts were made to grow the 5-azaC treated cells 
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T A B L E  2 5-azaC causes antigen reactive cells to proliferate to MO 
without antigen 
T ce l l s  ~ T r e a t m e n t  a M O  T T '  C P M  + S E M  a 
T T 1 8 M  - - - 1 ,241 -+ 133 
T T 1 8 M  - + - 777  -+ 125 
T T 1 8 M  - + + 2 , 1 8 1  -+ 39  
T T 1 8 M  5-azaC - - 791 -+ 27 
T T 1 8 M  5-azaC + - 1 3 , 9 6 8  -+ 1 ,932  
T T 1 8 M  5-azaC + + 6 , 3 4 3  -+ 712  
T T 1 8 I  - - - 9 1 6  -+ 76  
T T 1 8 I  - + - 2 2 6  +_ 4 6  
T T 1 8 I  - + + 3 , 0 0 3  + 3 2 8  
T T 1 8 1  5-azaC - - 3 3 6  +- 3 
T T I S I  5 -azaC + - 4 , 0 0 2  -+ 2 8 3  
T T 1 8 I  5 -azaC + + 1 ,499  -+ 141 
" I T 1 6 E  - - - 558  -+ 51 
T T 1 6 E  - + - 95 + 2 0  
T T 1 6 E  - + + 1 ,332  + 125 
T T 1 6 E  5-azaC - - 2 1 9  -+ 76  
T T 1 6 E  5-azaC + - 4 , 2 0 4  -+ 2 6 3  
T T 1 6 E  5-azaC + + 1 ,467  _+ 3 9 6  
q04  T cells were cultured with 104 autologous mitomycin-C treated MO, as described in Materials and Methods 
and Figure 1. 
bCells were treated with an optimal concentration o f  5-azaC, and used in these experiments at least 6 days after 
treatment. TT181 and T T I 8 M  responded optimally when treated with 1.0 IzM 5-azaC, while TT16E required 0.5 
~.M 5-azaC. 
' T T  was used at a final concentration o f  1:50. 
dResults are expressed as the mean -+ SEM of  triplicate cultures. 
by repeated stimulation with PBMCs alone. These experiments failed to maintain 
the lines. Similarly, attempts to subclone the treated cells by limiting dilution 
onto PBMCs without TT  also failed. These results suggest that the 5-azaC induced 
changes in T-cell reactivity are unstable. In other systems, 5-azaC induced changes 
may be stable, but clearly some are not [10], so these results remain consistant 
with the known effects of  5-azaC. 
In summary, these results demonstrate that 5-azaC induced self-reactivity is 
not unique to the TT18X cloned line, and that other  T4 + antigen-specific cloned 
lines display the same responses. In contrast, 5-azaC induced self-reactivity was 
not observed in two T8 +, TT  specific T-cell lines [34]. 
One potential explanation for the 5-azaC induced self-reactivity is that 5-azaC 
treated T cells may respond abnormally to the exogenous IL-2 used in the pro- 
liferation assay. To test for this, untreated and 5-azaC treated TT16E cells were 
cultured with equal numbers of  autologous mitomycin-C treated MO, with and 
without TT,  in the absence of  IL-2 (Figure 2). As can be seen, 5-azaC induced 
self-reactivity was still observed, with a maximum proliferation on day 4. Similar 
results were observed with TT18I  (data not shown). In Figure 2, the magnitude 
of  the proliferation induced by MO alone was greater than that induced by MO 
plus TT. This may reflect a change in the optimal number of  MO and optimal 
TT  concentration necessary for T-cell activation following 5-azaC treatment, 
although other  factors, such as more rapid growth of  self-reactive cells relative 
to nontransformed cells, cannot be excluded. Since 5-azaC induced self-reactivity 
was still observed despite withholding exogenous IL-2, the exogenous IL-2 prep- 
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FIGURE 2 Exogenous IL-2 is not required for 5-azaC induced autoreactivity. 104 un- 
treated TT16E (left panel) or 104Tl"16E treated with 0.5 /~M 5-azaC (right panel) were 
cultured with an equal number of mitomycin-C treated MO, or with 104 autologous MO 
plus TT at 1:50 final dilution. Proliferation was measured on days 2, 4, and 6 by 3H-TdR 
uptake. Each point represents the mean -+ SEM of triplicate cultures. Controls containing 
T cells cultured alone gave background proliferations of 552 + 21 CPM for TT16E and 
695 -+ 394 for TT16E treated with 0.5 /zM 5-azaC (mean -+ SEM of the three time 
points). The ordinate scale is the same in both panels. 
aration cannot be responsible for the proliferation observed. However ,  because 
exogenous IL-2 often augmented proliferative responses, subsequent assays were 
per formed using added IL-2. 
In many systems, 5-azaC has been demonstrated to induce gene expression 
by inhibiting D N A  methylation [9-16] .  However ,  some authors report  that 5- 
azaC can also induce gene expression through an undefined toxic effect on certain 
cell types [35]. To  determine whether  the self-reactivity induced by 5-azaC is 
due to inhibition of  D N A  methylation or another mechanism such as inhibition 
of  D N A  synthesis, TT18I  was treated with 5-azaC or hydroxyurea (HU) for 4 
days, then washed and tested for self-reactivity as before. H U  is an inhibitor of  
D N A  synthesis which does not affect D N A  methylation [36,37], but which has 
been demonstra ted to induce hemoglobin F synthesis in bone marrow cultures 
[35]. Cells treated with 12.5 /.~M H U ,  the highest concentration tested which 
does not kill IL-2 dependent  T cells, failed to induce self-reactivity, while 1.0 
/~M 5-azaC induced MO reactivity (Table 3). Lower concentrations of  H U  also 
failed to induce MO reactivity (data not shown), This indicates that 5-azaC induces 
M O  reactivity through mechanisms other than inhibition of  D N A  synthesis. 
5-azaC T r e a t e d  T 4  + Cells R e s p o n d  to Class I I  M H C  D e t e r m i n a n t s  
on  M O  
To  determine whether  5-azaC treated T4 + T cells are activated by class II M H C  
determinants  on MO, analogous to thymocytes,  monoclonal antibodies to frame- 
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TABLE 3 5-azaC but not hydroxyurea causes T4 + antigen reactive T cells to 
proliferate to MO without antigen" 
Exp.  I Exp.  II 
Cel ls  T r e a t m e n t  M O  T T  C P M  + SEM C P M  -+ SEM 
T T 1 8 I  5 -azaC -- - 1 ,154  .+ 64  2 , 8 1 9  .+ 558  
T T 1 8 I  5 -azaC + - 16 ,125  .+ 1 ,777 8 , 0 4 6  .+ 321 
T T 1 8 I  5 -azaC + + 2 0 , 4 6 7  -+ 2 , 1 1 2  13 ,332  -+ 2 , 1 4 6  
T T 1 8 I  H U  - - 2 , 2 2 4  -+ 5 5 8  8 0 3  -+ 232  
T T I 8 I  H U  + - 3 , 4 9 6  -+ 741 1 ,407  .+ 79  
"I*F18I H U  + + 9 , 9 2 7  -+ 85 2 8 , 1 1 1  + 1 ,299  
'~T cells were treated with 1.0 btM 5-azaC or 12.5 /zM H U  and 4 days later used for these studies. 104 treated T 
cells were cultured with equal numbers of  mitomycin-C treated autologous MO, and TT was used at a dilution of 
1:50. IL-2 was added on day 3 and proliferation measured on day 6 by ~H-TdR incorporation. 
work determinants on class I or class II MHC gene products were used to inhibit 
activation of cloned T cells by irradiated autologous MO (Table 4). As can be 
seen, monoclonal antibodies binding to framework determinants on HLA-A, 
-B, and -C molecules had no effect on activation of the T cells, while antibody 
to HLA-D molecules inhibited T-cell activation, suggesting that the T cells are 
recognizing and activated by class II MHC determinants on the MO. To further 
support this observation, studies were performed using allogeneic MOs. Table 
5 shows experiments in which 5-azaC treated TT specific T4 + T cells were 
cultured with autologous or allogeneic irradiated MOs. Autologous MOs acti- 
vated the T cells, while allogeneic MOs did not, indicating that the T cells 
recognize determinants unique to the autologous MO, such as MHC determi- 
nants. Taken together, the inhibition of T-cell activation by an HLA-D specific 
monoclonal antibody and the failure of allogeneic MOs to activate the T cells 
strongly suggests that the 5-azaC treated T cells are activated by the polymorphic 
determinants of self class II MHC molecules alone. 
Anti-T3 Antibodies  Inhibi t  Activat ion of  5-azaC Trea ted  T Cells 
To test whether the T3-Ti complex was involved in class II antigen induced 
proliferation, 5-azaC treated TT specific T4 + cells were again activated by au- 
tologous MOs, and monoclonal antibodies to the T3 and class I MHC molecules 
were used to inhibit the activation. Table 6 demonstrates that anti-T3 monoclonals 
TABLE 4 Monoclonal antibodies to HLA-D molecules inhibit activation of 
5-azaC treated T4 + T cells by macrophages without antigen ~ 
Exp.  1 Exp.  II Exp.  I l l  
Cel ls  M O  A n t i b o d y  C P M  .+ SEM C P M  -+ SEM C P M  + SEM 
T T 1 8 I  - - 1 ,345  + 107 2 , 6 3 3  + 6 9 7  7 1 0  + 103 
T F 1 8 1  + - 5 , 0 2 0  -+ 705  6 , 8 6 0  -+ 5 2 0  3 , 4 2 3  + 5 9 0  
T T I 8 I  + a n t i - H L A  A , B , C  5 , 0 7 0  -+ 7 6 6  6 , 7 2 7  .+ 5 5 6  4 , 2 1 1  .+ 1 ,438  
T T 1 8 I  + a n t i - H L A  D 2 , 9 5 2  .+ 8 0 9  3 , 1 9 8  -+ 5 9 6  1 ,077  + 573  
a104 T cells and 104 MO were cultured as described in Table 1. IL-2 was added on day 3 and proliferation measured 
on day 6 by 3H-TdR incorporation. No  antigen was added. Monoclonal antibody concentration were 100 ng/ml 
for anti-HLAA,-B,-C, and l ng/ml for anti-HLA-D. 
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TABLE 5 Allogeneic macrophages do not activate 5-azaC treated TT18V 
Exp. I Exp. II 
M O  D R  type  C P M  + SEM C P M  +_ SEM 
b 233 -+ 87 2 ,286  -+ 309 
4,4'  7 ,362 +- 158 6 ,024 +- 360 
1 , J  1,505 -+ 197 2,357 + 819 
4 , J  784 + 96 3,027 -+ 853 
3,5 439  -+ 166 nd d 
~104 TF181 cells were cultured with 104 MO as described in Table 1. No antigen was added. 
bNo MO added. 
'Autologous MO are 4,4. 
~Parents not typed. 
~nd = not done. 
inhibited this activation, while anti-HLA-A, -B, -C monoclonal antibodies did 
not. In these studies, aggregated anti-T3 antibody was removed by centrifugation 
at 100,000 x g and exogenous IL-2 was not added to the assay. Under these 
conditions, the OKT3 antibody blocked activation, rather than directly activating 
the cells. In other studies, anti-T4a monoclonal antibodies at 100 ng/ml failed to 
inhibit activation (data not shown). These data suggest that the activation of  
antigen specific T cells by class II MHC molecules alone involves the T3-Ti 
complex [ 3 8 - 4 2 ] .  One possible explanation for this observation is that 5-azaC 
induces a quantitative change in the amount of  the T3-Ti complex on the cells. 
To test for this, T3 expression of  treated and untreated cells was compared using 
flow cytometry. N o  significant quantitative change in T3 was induced on the cells, 
and light scatter measurements showed the size of  the treated and untreated cells 
was similar (data not shown). This suggests that a quantitative change in the 
amount of  surface T3 is not responsible for the self-reactivity. 
T A B L E  6 OKT3 inhibits activation of  5-azaC treated T4 + cells by 
macrophages without antigen ~ 
E x p e r i m e n t s  Cel l s  M O  A n t i b o d y  C P M  _+ SEM 
1 T T 1 8 I  - - -  710 -+ 59 
TT181 + - -  2 ,288 -+ 39 
T r l 8 1  + an t i -HLA A,B,C 2 ,804 _+ 639  
T T 1 8 I  + O K T 3  598 -+ 107 
2 T T 1 6 E  - - -  626 _+ 435 
T T 1 6 E  + - -  3 ,059 -+ 370 
T T 1 6 E  + a n t i - H L A  A,B,C 2,092 +- 169 
T T 1 6 E  + O K T 3  848 +- 438 
3 T T 1 8 I  - O K T 3  832 -+ 148 
TT181 + a n t i - H L A  A,B,C 3 ,469 + 471 
T T 1 8 I  + O K T 3  842 + 232 
~r4 + cloned T-cell lines were treated with 0.5-1.0 /aM 5-azaC as before. T cells were cultured as described in 
Table 1, except that no exogenous IL-2 was added and proliferation measured on day 5. Cell density was 104 T 
cells and 104 MO/well. Monoclonal antibodies were used at 100 ng/ml. OKT3 was centrifuged at 100,000 x g for 
15 min immediately prior to use. 
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The  Surface Phenotype  of  5-azaC Trea ted  T4 + Cells Does Not  Change 
T cells maturing in the thymus also express a defined series of surface molecules 
identified by monoclonal antibodies. The Common, or stage II thymocyte, ex- 
presses the phenotype T6 ÷ T4 + T8 ÷ T3- .  Mature thymocytes and T cells are 
either T6 -  T4 ÷ T8 T3 + or T6-  T4 -  T8 ÷ T3 ÷ [6,7]. To test whether surface 
phenotype was also changed by 5-azaC treatment, T4, T6, and T8 expression 
were evaluated by flow cytometry before and after 5-azaC treatment. The 5-azaC 
treated cells remained T4 + T8 - ,  and total T4 expression was not changed (data 
not shown). Similarly, T6 was not induced. In contrast, 5-azaC can be shown to 
induce T4 expression on T8 ÷ cells [34]. In some systems, sodium butyrate acts 
synergistically with 5-azaC to induce gene expression, via a mechanism involving 
both DNA methylation and histone acetylation [ 16,43-46]. Accordingly, 5-azaC 
treated T4 + cells were treated with 1-10 mM sodium butyrate. No detectable 
T8 was induced. These results demonstrate that expression of the T8 determinant 
is either not regulated by methylation, or that additional mechanisms beyond 
DNA methylation regulate these molecules. 
DISCUSSION 
The data presented in this report demonstrate that cloned, T4 ÷ antigen reactive 
human T-cell lines treated with 5-azaC, but not hydroxyurea, can be activated 
by autologous MOs in the absence of antigen. The observations that monoclonal 
antibodies to HLA-D determinants inhibit this activation, and that allogeneic 
MOs fail to activate the cells, indicate that the treated T cells are recognizing 
class II MHC gene products on the MO. The observation that MO from a second 
DR4 donor did not activate 5-azaC treated T cells may be due to the T cell 
identifying D region products not identified by currently available typing sera 
and unique to the T-cell donor. The most likely interpretation of these obser- 
vations is that 5-azaC induces expression of as yet unidentified genes involved 
in thymocyte activation but suppressed by mechanisms involving DNA methy- 
lation in mature T cells. 5-azacytidine has been demonstrated to induce gene 
expression in other systems by inhibiting methylation of newly synthesized DNA 
[9-16,47]. For example, 5-azaC has been used to change the metastatic growth 
characteristics of tumor cells [ 19], change fibroblasts and undifferentiated embryo 
cells into adipocytes, chondrocytes and muscle cells [15,20], induce IL-2 pro- 
duction in nonsecreting thymoma cells [21], induce the macrophage-like prop- 
erties of phagocytosis, cytoplasmic granules, and vacuoles in B-lymphocyte cell 
lines [22], and transform myoblasts into myofibers [23]. Many of these trans- 
formations are unstable, although some are not [10]. Therefore, the observation 
that the 5-azaC induced self-reactivity became unstable after 2 weeks is still 
consistant with the described effects of 5-azaC. 5-azaC has other effects on cellular 
metabolism, such as inhibition of DNA synthesis [48], and can induce expression 
of certain genes presumably via these mechanisms. It is unlikely that this non- 
specific effect is responsible for the changes induced in T4 ÷ T cells, since hy- 
droxyurea, an inhibitor of DNA synthesis which does not affect DNA methyl- 
ation, does not induce MO reactivity. This observation suggests that 5-azaC is 
acting via inhibition of methylation [36,37,47]. Experiments testing this hypoth- 
esis are underway. 
The hypothesis that 5-azaC induces gene(s) which enable T cells to respond 
to class II MHC antigens alone is consistant with thymocyte responses observed 
during T-cell maturation. During maturation, thymocytes are induced to prolif- 
erate, apparently by class II MHC determinants alone [1,3], but mature T cells 
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must bind both MHC molecules and antigen for activation to occur. Methylation 
of  crucial genes may occur during thymic maturation resulting in the requirement 
for mature T cells to identify both antigen and class II molecules for activation. 
One candidate for a gene that could alter T-cell specificity, and which is 
suppressed during the maturation of  T4 + cells, is the ~/ chain of  the T-cell 
receptor.  This gene is initially coexpressed with the/3 chain gene in immature 
thymocytes. Cells that ultimately become T4 ÷ suppress ~/chain expression and 
activate the c~ chain gene [49,50]. The 5/3 receptor,  on T cells destined to become 
T4+,  may recognize autologous class II MHC molecules with sufficient avidity 
to activate the cell, committing it to the T4 ÷ lineage. Suppression of the ~/chain 
could serve to decrease the receptor affinity, allowing HLA-D recognition through 
the/3 chain, but with too low avidity for activation to occur. A necessary corollary 
of  this hypothesis would be that the ~ chain serves as the antigen recognition 
unit. If the ~ chain also recognized HLA-D molecules with sufficient avidity to 
activate the cell as an c~/3 receptor,  the cell would have to be eliminated, rather 
than be released from the thymus. Experiments testing ~/chain expression in 5- 
azaC treated T4 + cells are underway. 
A second, but less likely, explanation for the reactivity changes induced by 5- 
azaC is that all four cloned lines tested may contain a subset of  T cells that 
respond to class II molecules alone or in conjunction with some unidentified 
molecule(s) present in the tissue culture system. Such reactivity is referred to as 
the autologous mixed lymphocyte reaction, or AMLR [51-55] ,  and is also in- 
hibited by anti-class II monoclonal antibodies and anti-T3 antibodies [56]. This 
subset would have to be consistantly selected for by 5-azaC to explain these 
observations. Moreover,  the induction of self-reactivity by 5-azaC has been ob- 
served in four out of  four lines tested. Finally, self-reactivity has not been ob- 
served among these cells without 5-azaC treatment. For these reasons it is unlikely 
that the observed effects are due to a contaminating AMLR responsive T-cell 
subpopulation among the TT  reactive cells. 
The  observation that anti-T3 antibodies inhibit activation of the 5-azaC treated 
T cells by class II MHC molecules alone is interesting. The T3 family of  molecules 
are noncovalently attached subunits of the clonally distributed T-cell receptor 
[38,40]. Antibodies to this complex inhibit antigen reactivity, alloreactivity, and 
AMLR reactivity [38,39,56,57], implicating this receptor in the recognition of  
antigenic determinants and/or class II MH C determinants. Since 5-azaC treated 
cloned TT  reactive T cells are activated by class II MHC determinants without 
TT,  the inhibition by anti-T3 antibodies implies that this receptor complex is 
involved in recognition of  class II MHC molecules. A second possibility is that 
anti-T3 antibodies may deliver an inhibitory signal to the T cell, preventing 
activation of  the cell through a separate MH C receptor. This possibility is difficult 
to evaluate at this time, as this receptor would need to be independent of the 
T3 molecules. Quantitative changes in the expression of  the T3-Ti complex could 
also potentially alter the activation requirements for the cells. However ,  this 
latter mechanism is unlikely as total T3 expression could not be shown to change 
with 5-azaC treatment. 
Antigen-specific murine T-T hybrids have also been activated by class II de- 
terminants alone [58,59]. One reason that hybrids, but not normal antigen re- 
active T cells can be activated by MHC products alone, may be related to the 
abnormal genetic regulation of  malignant cells and their hybrids. Moreover,  ac- 
tivation in these systems is measured by lymphokine secretion, as the cells are 
already proliferating, and regulation of lymphokine secretion may differ from 
proliferation. 
The relationship of  AMLR reactive T cells and 5-azaC treated antigen reactive 
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T cells is unknown. The AMLR may represent  normal antigen-specific T cells 
with crucial genes activated which allow it to respond to self class II molecules 
alone, analogous to 5-azaC treated cells. An alternative view is that the AMLR 
represents  T cells activated by undefined antigens present  in tissue culture systems 
and presented by MOs [52] or  that there exists a subset o f  mature T cells capable 
of  responding to self M H C  products alone [51,54] possibly involved in immune 
regulation [54,60,61]. These possibilities may be sorted out if genes activated 
by 5-azaC can be identified and their expression tested in AMLR reactive cells. 
A final point  o f  interest is that the induction of  T-cell reactivity to class II 
M H C  molecules alone by 5-azaC represents induction of  autoreactivity in a 
normal T cell. This observation suggests that normal T cells can be made auto- 
reactive by chemicals or other agents, possibly viruses, which activate genes 
responsible for self-reactivity. Such cells could play a role in autoimmune diseases. 
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